Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 2/20 | 0.43 |
| ▸ | DCPS | Q96C86 | 2/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19519745 | 0.84 | MCHR1 (0.44) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL11673199 | 0.83 | ALDH1A1 (0.53) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL8940216 | 0.81 | ALDH1A1 (0.52) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL10746717 | 0.81 | ALDH1A1 (0.52) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL11323988 | 0.80 | ALDH1A1 (0.53) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL28935895 | 0.80 | ALDH1A1 (0.50) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL11267013 | 0.79 | ALDH1A1 (0.49) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL177279 | 0.78 | ALDH1A1 (0.55) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL15060240 | 0.78 | ADRA2A (0.42) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL29165171 | 0.78 | ALDH1A1 (0.47) | ALDH1A1HPGDHTTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349846-B2 | Fused pyrimidine derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2013-01-08 | — | — | US | disclosed |
| US-20100292254-A1 | Fused Pyrimidine Derivatives as Trpv3 Modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-11-18 | — | — | US | disclosed |
| EP-2229388-A2 | FUSED PYRIMIDINE DERIVATIVES AS TRPV3 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009109987-A2 | FUSED PYRIMIDINE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-7360883-B2 | Active ray curable ink, image forming method and ink-jet recording apparatus | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2008-04-22 | — | — | US | disclosed |
| US-20050190252-A1 | Active ray curable ink, image forming method and ink-jet recording apparatus | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292254-A1 | Fused Pyrimidine Derivatives as Trpv3 Modulators | TRPV3, TRPV1, TRPV5 | ALDH1A1 4233/4885HPGD 1055/4885HTT 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.